JANUARY 19, 2021

Biophytis receives DMC recommendation for starting recruitment for Part 2 of its Phase 2-3 COVA study in COVID-19

Read the Press Release

Other Press Releases

Biophytis today announced the submission of the registration filing for its joint venture in Hong Kong with its Asian partners, including Ronghui Renhe Life Technology, a leading Chinese conglomerate primarily…

Read more

Biophytis provides an update on the modification of the terms of the straight bond financing facility established with Hexagon Capital Fund (“Hexagon”) on August 5, 2025, amended for the first…

Read more

Biophytis announces that it took part in NVIDIA’s world-renowned GTC conference, the ultimate global stage for AI innovation. Held from March 16 to 19, 2026, Biophytis participated at NVIDIA GTC,…

Read more

Biophytis SA announces that it participated in the Intrinsic Capacity, Frailty and Sarcopenia Research Conference for Healthy Longevity (ICFSR), held from March 10 to 12, 2026 in Washington, DC (United…

Read more

Biophytis and LynxKite launch new modalities beyond MASSIVE: AI-driven drug discovery for next-generation longevity therapies This partnership will generate revenue through: A computational longevity platform, including unique curated datasets and…

Read more

Biophytis SA today announces the completion of a capital increase trough the issue of new shares each accompanied by a share subscription warrant, with the removal of the preferential subscription…

Read more